Jesús Porta-Etessam

Has grant

Professor

Universidad Alfonso X el Sabio
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

promoción e impulso de la investigación biomédica

Open Date: 2016-10-01

Close Date: 2017-10-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Introduction Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine. Methods Observational, multicenter, prospective cohort study. The 50%, 75% and 30% responder rates, between weeks 8–12 and 20–24, were compared with the baseline. Treatment emergent adverse effects were systematically evaluated. Response predictors were estimated by multivariate regression models. Results Eighty-six patients were included, 79.1% females, aged 39.5 (inter-quartile range [IQR] 26.3–50.3), with chronic migraine (43.0%), medication overuse headache (55.8%) and a median of two (inter-quartile range: 0.75–3) prior preventive treatments. At baseline patients had 14 (10–24) headache and 8 (5–11) migraine days per month. The 30%, 50% and 75% responder rates were 40%, 34.9% and 15.1% between weeks 8–12, and 48.8%, 36%, and 18.6% between weeks 20–24. Adverse effects were reported by 30 (34.9%) and 13 (15.1%) patients between weeks 0–12 and 12–24, leading to discontinuation in 15 (17.4%) patients. Chronic migraine, depression, headache days per month, medication overuse headache, and daily headache at baseline predicted the response between weeks 20–24. Conclusion Candesartan effectiveness and tolerability in migraine prevention was in line with the clinical trials’ efficacy. Trial registration: The study protocol is registered in ClinicalTrials.gov (NCT04138316).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (11)

Alex Jaimes

Universidad Autónoma de Madrid

SPAIN
View details

María-Luz Cuadrado

Universidad Complutense de Madrid

SPAIN
View details

Andrés Soto-Varela

Jefe de Servicio y Profesor Titular

Servicio Andaluz de Salud

SPAIN
View details

Lidiane Lima Florencio

Profesor

Universidad Rey Juan Carlos

SPAIN
View details

Marcos Polanco Fernández

Marqués de Valdecilla University Hospital

SPAIN
View details

Albert Muñoz-Vendrell

Multiple Sclerosis Unit | Headache Unit

Bellvitge University Hospital

SPAIN
View details

Francisco Javier Domingo Espineira

Associate Professor (Lecturer)

Universidad a Distancia de Madrid (UDIMA)

SPAIN
View details

Óscar Fraile Martínez

Universidad de Alcalá

SPAIN
View details

Margarita Sanchez Del Rio

Headache specialist

Clinica Universidad de Navarra

SPAIN
View details

SANTOS LASAOSA

professor

Universidad de Zaragoza

SPAIN
View details

Angel Luis Guerrero-Peral

Universidad de Valladolid

SPAIN
View details